WM-8014: Selective KAT6A/B Inhibitor for Epigenetic and Cancer Research

Executive Summary: WM-8014 is a competitive, reversible inhibitor targeting the MYST family of histone acetyltransferases, including KAT6A and KAT6B, with IC₅₀ values of 8 nM and 28 nM, respectively (APExBIO). It occupies the acetyl-CoA binding site on the MYST domain, directly competing with acetyl-CoA and forming hydrogen bonds similar to the diphosphate group of the cofactor (bioRxiv). WM-8014 induces cell cycle arrest and promotes cellular senescence via the p16^INK4A–p19^ARF pathway, without general cytotoxicity in mouse embryonic fibroblasts. The compound was shown to reduce KRAS^G12V-driven liver overproliferation in zebrafish, with minimal impact on normal liver growth. Its high selectivity and non-cytotoxic senescence induction make it a central tool for dissecting epigenetic dependencies in cancer biology and cell cycle research.

Biological Rationale

Histone lysine acetyltransferases (HATs) such as KAT6A (MOZ) and KAT6B (MORF) regulate gene expression by catalyzing the transfer of acetyl groups to lysine residues on histone tails. Dysregulation of these enzymes is implicated in oncogenesis, particularly in pathways governing cellular senescence and proliferation (bioRxiv). Selective inhibition of KAT6A/B has emerged as a promising approach to arrest tumor growth through the induction of oncogene-induced senescence. WM-8014, developed and distributed by APExBIO, is designed to selectively target KAT6A and KAT6B, as well as KAT5 and KAT7, enabling researchers to dissect the role of MYST family acetyltransferases in epigenetic regulation and cancer biology (histone-h2a.com). This article extends prior coverage by providing atomic, benchmarked claims and workflow integration details not found in existing literature.

Mechanism of Action of WM-8014

WM-8014 is a highly potent, selective, and reversible inhibitor of the MYST family HATs KAT6A, KAT6B, KAT5, and KAT7. Its IC₅₀ values are 8 nM for KAT6A, 28 nM for KAT6B, 224 nM for KAT5, and 342 nM for KAT7, as determined by in vitro enzymatic assays (APExBIO). The compound acts by directly competing with acetyl-CoA at the substrate-binding domain. The acyl sulfonyl hydrazide core of WM-8014 forms hydrogen bonds that mimic the diphosphate group of acetyl-CoA, stabilizing its binding to the MYST domain and inhibiting enzymatic activity (bioRxiv). This competitive inhibition prevents the acetylation of histone lysine residues, leading to altered chromatin structure and transcriptional repression of key cell cycle genes. The reversibility of binding allows for precise temporal modulation in experimental systems. For a deeper mechanistic review, see WM-8014: Unveiling Epigenetic Vulnerabilities Beyond KAT6, which this article updates by detailing context-specific benchmarks and practical integrations.

Evidence & Benchmarks

• WM-8014 inhibits KAT6A, KAT6B, KAT5, and KAT7 with IC₅₀ values of 8 nM, 28 nM, 224 nM, and 342 nM, respectively (enzyme assay, pH 7.5, 25°C) (APExBIO).
• The compound directly competes with acetyl-CoA, occupying the cofactor binding site and blocking substrate access (crystallographic evidence, Figure 2C) (bioRxiv).
• In primary mouse embryonic fibroblasts (E14.5 MEFs), WM-8014 treatment (1 μM, 48 h) induces cell cycle arrest and senescence via upregulation of Cdkn2a (p16^INK4A–p19^ARF), with no increase in cytotoxicity measured by viability assay (n=3, triplicate) (bioRxiv).
• RNA-seq profiling of WM-8014-treated MEFs reveals upregulation of Cdkn2a and downregulation of Cdc6, a direct KAT6A target involved in DNA replication (see Supplementary Table 1) (bioRxiv).
• In a zebrafish model of KRAS^G12V-driven hepatocellular overproliferation, WM-8014 (0.5–5 μM, 72 h) reduces liver volume and cell proliferation in a dose-dependent manner, sparing normal liver growth (n=12 per group) (bioRxiv).
• Solubility of WM-8014 in water is ~8–16 μM; it is insoluble in ethanol (solubility determination, room temperature) (APExBIO).
• WM-8014 exhibits high plasma-protein binding in mouse serum, limiting in vivo efficacy; WM-1119 is the recommended alternative for in vivo studies (APExBIO).

Applications, Limits & Misconceptions

WM-8014 is a tool compound for dissecting the function of histone acetyltransferases, particularly in pathways involving cell cycle arrest, senescence, and oncogene-driven proliferation. Its selectivity allows researchers to modulate the p16^INK4A–p19^ARF pathway without inducing global cytotoxicity. Key research applications include:

• Epigenetic regulation and chromatin modification studies.
• Oncogene-induced senescence induction via cell cycle arrest assays.
• Tumor growth arrest compound for in vitro and zebrafish models.
• Elucidation of senescence pathways in primary cells and cancer cell lines.

For practical scenarios and lab troubleshooting, see Solving Laboratory Challenges with WM-8014 (SKU A8779), which this article extends with latest evidence and updated benchmark data.

Common Pitfalls or Misconceptions

• Not suitable for systemic in vivo mouse studies: High plasma-protein binding greatly reduces free WM-8014, limiting efficacy; use WM-1119 for animal studies (APExBIO).
• Does not induce pan-cytotoxicity: WM-8014 induces senescence and cell cycle arrest, but does not cause general cell death in non-transformed cells (bioRxiv).
• Solubility constraints: Compound is only soluble in water up to 8–16 μM; do not attempt to dissolve in ethanol.
• Specific to MYST family HATs: Ineffective against non-MYST histone acetyltransferases or unrelated chromatin modifiers.
• Not a direct DNA demethylating agent: Its effects are mediated through acetylation inhibition, not DNA methylation changes.

Workflow Integration & Parameters

WM-8014 (SKU A8779) is supplied as a research-use-only reagent by APExBIO. Store the compound at -20°C in dry conditions. Prepare aqueous stock solutions at ≤16 μM; avoid long-term storage of diluted solutions to prevent hydrolysis. For cell culture experiments, typical working concentrations range from 0.1 μM to 5 μM, optimized per assay and cell type (APExBIO). Confirm solubility in chosen buffer before use. In cell cycle arrest or senescence induction assays, treat for 24–72 hours and monitor gene expression and viability. For in vivo zebrafish studies, titrate concentrations for specific endpoints. For detailed integration strategies, see the broader review Unlocking the Future of Epigenetic Therapy, which this article clarifies by mapping exact storage, solubility, and application limits.

Conclusion & Outlook

WM-8014 is a validated, selective, and reversible KAT6A/B inhibitor with nanomolar potency. Its ability to induce oncogene-induced senescence without cytotoxicity makes it a critical tool for dissecting epigenetic dependencies in cancer biology and cell cycle research. Limitations in systemic in vivo studies highlight the importance of proper workflow integration and the use of derivatives such as WM-1119 for animal work. WM-8014 exemplifies the next generation of epigenetic drug target inhibitors, enabling researchers to precisely modulate histone acetylation and uncover new therapeutic strategies. For ordering, specifications, and safe handling, refer to the product page: WM-8014.